Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN : to Develop QuantiFERON®-TB Access as a New Test for Low-Resource, High-Burden Regions in Global Fight Against TB

share with twitter share with LinkedIn share with facebook
share via e-mail
01/07/2019 | 02:04am EDT

Adapting the power of QuantiFERON®-TB technology to advance global TB control efforts in new partnership with Ellume

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to develop a proprietary new version of a QuantiFERON®-based tuberculosis (TB) test dedicated and tailored to the needs of low-resource regions with a high disease burden of TB.

The new testing solution, QuantiFERON®-TB Access (QFT® Access), is designed to pair ultrasensitive digital detection of latent TB infection with a complete workflow created with a focus on cost efficiency and ease of use. QIAGEN is developing QFT Access in a new partnership with Ellume, an Australian developer of high-performance digitally-enabled diagnostics. Clinical trials for QFT Access are planned to start in 2019, and commercialization is expected to begin in 2020.

QFT Access has been designed to advance TB control in areas with limited infrastructure, including countries in Asia, Africa and Latin America. The World Health Organization (WHO) has classified a group of 30 countries in these regions as high-burden, representing an estimated 85% of the global TB burden. QIAGEN intends to work with the WHO, various non-governmental organizations and governments to support their TB control efforts, in particular to achieve the goals set for the WHO's End TB Strategy.

“QuantiFERON-TB Gold Plus is rapidly winning adoption in developed markets as an important way to detect latent TB infections and prevent patients from developing the active form of this potentially deadly disease,” said Thierry Bernard, Senior Vice President of QIAGEN’s Molecular Diagnostics Business Area. “Despite the urgent need for more latent TB testing in low-resource, high-burden parts of the world, a lack of infrastructure and shortage of trained technicians make adoption of modern tests challenging. QuantiFERON-TB Access offers a novel solution for this challenge by combining the proven clinical insights of QuantiFERON-TB with Ellume’s digital technologies to deliver cost-efficient results quickly and without need for a laboratory, and a further signal of our support in the global fight against TB.”

Please find the full press release here.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN N.V.
06/04QIAGEN NV : Downgraded from Neutral to Sell by Independant Research
MD
06/02QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/29QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
05/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/28QIAGEN : Builds on Leading Position in Precision Medicine With Novel Solutions i..
BU
05/20QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/19THERMO FISHER SCIENTIFIC : Publishes Offer Document for Voluntary Tender Offer f..
AQ
05/18QIAGEN N : Announces Publication of Reasoned Position Statement for Proposed Acq..
BU
05/17Coronavirus Vaccine Frontrunners Emerge, Rollouts Weighed
DJ
05/08QIAGEN N.V. : Release of a capital market information
EQ
More news
Financials (USD)
Sales 2020 1 689 M - -
Net income 2020 253 M - -
Net Debt 2020 912 M - -
P/E ratio 2020 37,3x
Yield 2020 -
Capitalization 10 130 M 10 130 M -
EV / Sales 2019
EV / Sales 2020 6,54x
Nbr of Employees 5 100
Free-Float 97,2%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 40,42 $
Last Close Price 44,36 $
Spread / Highest target 12,7%
Spread / Average Target -8,89%
Spread / Lowest Target -30,1%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.31.24%10 130
LONZA GROUP32.67%36 393
IQVIA HOLDINGS INC.-2.14%28 876
CELLTRION, INC.41.71%27 183
SEATTLE GENETICS, INC.31.66%26 040
MODERNA, INC.209.76%23 559